Invention Grant
- Patent Title: Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
-
Application No.: US17269706Application Date: 2019-08-20
-
Publication No.: US11939582B2Publication Date: 2024-03-26
- Inventor: Steven Petrou
- Applicant: RogCon, Inc.
- Applicant Address: US FL Miami Beach
- Assignee: RogCon, Inc.
- Current Assignee: RogCon, Inc.
- Current Assignee Address: US FL Miami Beach
- Agency: McCarter & English, LLP
- Agent Jonathan M. Sparks; Yelena Margolin
- International Application: PCT/US2019/047313 2019.08.20
- International Announcement: WO2020/041348A 2020.02.27
- Date entered country: 2021-02-19
- Main IPC: C12N15/11
- IPC: C12N15/11 ; A61K9/00 ; A61P25/00 ; C12N15/113
Abstract:
Provided herein are methods, compounds, and compositions for reducing expression of sodium voltage-gated channel alpha subunit 2 (SCN2A) in a subject. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a sodium voltage gated channel alpha subunit 1 (SCN1A) related disease or disorder (e.g., Dravet syndrome) in a subject in need.
Public/Granted literature
- US20210317462A1 ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES Public/Granted day:2021-10-14
Information query
IPC分类:
